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The solid state environment orchestrates embryonic development and
tissue remodeling. Cell interactions with extracdllular matrix and with
other cells play critical roles in morphogersesis during development and in
tissue homeostasis and remodeling throughout life. Extracellular matrix is
information-rich, not only because it is comprised of multifunctional
structural ligands for cell surface adhesion receptors, but also because it
contains peptide signaling factors, and proteinases and their inhibitors.
The functions of these groups of molecules are extensively interrelated. In
this review, three primary cell culture models are described that focus on
adhesion receptors and their roles in complex aspects of morphogenesis
and remodeling: the regulation of proteinase expression by fibronectin and
integrins in synovial fibroblasts; the regulation of osteoblast differentiation
and survival by fibronectin, and the regulation of trophoblast differentia-
tion and invasion by integrins, cadherins and immunoglobulin family
adhesion receptors.
During development, the embryo establishes a series of prelim-
inary body plans, each of which is a remodeled and refined version
of the previous plan. Although the genetic blueprint is crucial, the
position of cells within the developing embryo, and the solid-state
environment of other cells and extracellular matrix (ECM),
provide a continually changing context within which to interpret
and execute the genetic program. ECM is extremely complex,
containing a large number of modular structural components,
such as collagens, proteoglycans and glycoproteins that interact
with one another and with cells. Although the ECM plays a critical
role as a scaffold on which and within which to organize tissues,
the ECM also contains an immense amount of information. Cells
must be able to decode this information, respond to it and modify
the information within the ECM continually, not only during their
differentiation, but throughout their lifespan in the mature organ-
ism. Thus, cells require a broad and highly regulated repertoire of
receptors for ECM (and for other cells) to be able to take
advantage of the information in this solid state environment. The
integrin and cell surface-associated proteoglycan (such as synde-
cans, CD44) families of receptors provide such a repertoire for
structural ECM components. Structural ligands are not the only
critical molecules in the ECM, however. Growth/differentiation
factors (peptide signaling factors [11) and proteinases and their
inhibitors [2, 3] are also sequestered in the ECM, or are tethered
to the cell surface.
The ECM and receptors for ECM and other cells, growth
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factors and their ligands, and matrix remodeling proteinases and
their inhibitors provide a solid state environment that orchestrates
the morphogenetic program during development, as well as tissue
homeostasis. The activities of these groups of molecules are
interrelated. Thus, the addition of growth factors such as vascular
endothelial growth factor stimulates expression of a distinctive
repertoire of integrins [4] and increases proteinase production [5]
by endothelial cells undergoing an angiogenic response. Similarly,
an addition of TGF-13 enhances ECM and ECM receptor produc-
tion and reduces net proteolytic activity in many cell types [61. The
equation can also work in the other direction. In our own work,
using synovial fibroblasts, we have shown that subtle changes in
ECM composition can trigger enhanced expression of MMP
[7—to]. The kinds of changes in ECM composition that are
capable of triggering enhanced MMP are remarkably specific
(Table 1). However, one generalization appears to be valid at least
for fibroblasts. Intact matrix components that are not subject to
intricate regulation in a given tissue, such as FN, collagen I and
vitronectin, promote basal levels of proteinase expression. How-
ever, certain fragments of these molecules [such as the central cell
binding domain of FN (FN 1117b0, or 12OFN)J, that would, for
example, be generated in wounds or sites of inflammation [11, 12],
induce elevated MMP expression [7, 9]. In addition, specific
combinations of an intact ECM component and any one of the
matricellular matrix components [131 that are transiently ex-
pressed at sites of morphogenesis or tissue remodeling and repair
[such as tenascin (TN), decorin, or secreted protein acidic and
rich in cysteine (SPARC)1 are also inductive [8, 10, 141. Three
points are illustrated by these data. Firstly, cell surface receptors
for ECM are important sensors and regulators of ECM homeosta-
sis. Secondly, many specific combinations of ECM components
can trigger enhanced MMP expression in fibroblasts, and thirdly,
the effects of these ECM components on MMP do not necessarily
correlate with the degree of cell spreading or the ability to organize
focal contacts (FC) [9], two other kinds of signals that cells receive
from ECM. Thus, cells independently process multiple signals from
even a simple, highly defined ECM environment.
A further feature of the regulation of MMP expression by ECM
is that multiple signaling pathways are possible. One pathway is
largely cell shape/FC-independent, highly substrate-specific and
direct. This is illustrated by the example of the I 2OFN cell binding
domain, 12OFN + the C-terminal heparin binding domain of FN,
or the combinations of TN with intact FN [7—9]. All these matrices
promote extensive spreading and, with the exception of I2OFN,
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Table 1. Regulation of metalloproteinase expression by extracellular
matrix composition in synovial fibroblasts
ECM composition MMP-1 expression
Fibronectin (FN) Low
Collagen I (Col I) Low
Vitronectin (VN) Low
12OFN
I2OFN + CS-F'
High
Low
L2OFN + HBDC High
anti-integrin aS High
anti-a5 + anti-cr4 Low
FN + tenascin (TN) HighColI+TN Low
TN+VN Low
VN + decorin High
Col I + decorin Low
FN + decorin Low
SPARCd and fibrillar collagens High
Immobilization of ECM ligands described in [7—10]
h CS-i, amino acids 1-25 of the IIICS (or V) alternatively spliced
domain of FN, binds cs4fll.
HBD: the C-terminal heparin binding region of FN. Type III repeats
12—14
d SPARC (secreted protein, acidic and rich in cysteine) in the appro-
priate ECM contexts regulates MMP indirectly by inducing a soluble
factor that triggers MMP [14]
focal contact formation, in synovial fibroblasts. They all also
induce enhanced levels of MMP (in the case of the mixed FN/TN
matrix, the region of the TN that initiates the proteinase inductive
signal is distinct from that which disrupts focal contact formation
by fibroblasts [8]). In this direct pathway, the signal is transduced
by integrins (such as a5f31 in the case of FN fragment inducers)
and the induction of mRNA for MMP-1 (interstitial collagenase)
is rapid. Within 10 minutes of plating synovial fibroblasts on an
inductive ECM (such as 12OFN or FN/TN), c-fos, a component of
the AP-1 transcription factor complex, is translocated to the
nucleus. Transcription of additional AP-i components is required
for the subsequent up-regulation of MMP-1, as inclusion of
antisense oligonucleotides for c-fos blocks elevation of MMP-1
levels. AP-1 and PEA-3 binding sites in the MMP-1 promoter are
required for expression in response to the 12OFN signal [15]. Since
immobilized anti-integrin a5 monoclonal antibody can replace
12OFN as an inductive substrate, it is clear that the a5/31 integrin
is able to transduce the 12OFN signal [7, 9, 15]. Whether other
integrins or cell surface proteoglycans participate in transducing
inductive signals from FN fragments is unclear, as are the
identities of the signal transducing receptors for the FNITN and
VN/decorin signals.
Since anti-integrin a5, I 2OFN and smaller FN fragments that
contain the RGD sequence all induce elevated MMP when
immobilized on the substrate, whereas intact FN signals cells to
produce a low basal level of MMP, other region(s) of FN must
contain information to control the inductive signal from the
central cell binding domain. Interestingly, the 25 amino acid CS-i
sequence from the alternatively spliced V region of FN is neces-
sary and sufficient to suppress the MMP-inducing 12OFN signal.
This sequence binds the a4/31 integrin, which is highly expressed
on synovial fibroblasts. Thus, two different /31 integrins coopera-
tively regulate MMP expression in vitro in response to FN in these
cells [9].
In the direct pathway described above for signaling elevated
MMP, the level of specificity in the matrix combinations that are
inductive for MMP is remarkable. Thus, TN/collagen I and
TN/VN are not inductive, whereas TN/FN is inductive [8]. In
another example, decorin/VN is inductive but decorin/collagen I
and decorin/intact FN are not, even though decorin binds to all
three components [10]. The ability of decorin to regulate MMP
expression in certain ECM contexts may be relevant to the
observation that decorin limits matrix accumulation, and is there-
fore important for maintaining matrix homeostasis in normal
tissues. This property has intrigued investigators interested in
therapeutic targets to block excessive matrix accumulation in
fibrotic diseases. Since decorin sequesters TGF-p, a known in-
ducer of ECM, it is logical to propose that decorin suppresses
ECM accumulation by limiting the availability of TGF-/3 [16].
There are now extensive data to support this idea [17, 18]. In
addition, however, it is possible that in certain matrix environ-
ments where VN and decorin are found together, decorin could
also limit ECM accumulation and help to promote resolution of
an acute fibrotic response by enhancing MMP expression and
therefore ECM turnover.
Additional pathways for ECM regulation of MMP expression
differ in important ways from the direct ligand specific pathway
described above. For example, triggering cell rounding in fibro-
blasts by undermining integrin-mediated cell spreading will in-
duce MMP regardless of which ligand was interacting with the
cells. A second example involves an indirect pathway. In this case
SPARC in combination with many different ECM components
(FN or fibrillar collagens, but not laminin) first induces a soluble
factor that then stimulates MMP expression. Since the domain in
SPARC responsible for this induction pathway is distinct from
that which undermines FC formation by cells on FN or collagens,
this pathway, like the direct pathway, is cell-shape independent
[14]. At this time, both the receptor(s) responsible for transducing
the inductive signal in the SPARC pathway and the identity of the
intermediate soluble factor produced are unknown. Taken to-
gether, our results in the synovial fibrohiast system illustrate
clearly, at the cellular level at least, the principle stated at the
outset of the review that the principal groups of molecules
residing in the ECM act coordinately to modulate the cellular
environment, and that alterations in the environment then act
back on the cells. The relatively simple system just described, that
is, primary synovial fibroblasts on highly defined ECM, is well
suited for continuing to work out how signals from specific ECM
environments are transduced to the transcription machinery of
the nucleus to regulate ECM homeostasis.
The discussion above relates to the regulation of matrix degrad-
ing proteinase expression by signals transduced by integrins (and
perhaps other classes of ECM receptor). An intriguing new twist
to the relationship of adhesion and proteolysis relates to the
plasminogen activator system [19, 20]. Both urokinase plasmino-
gen activator receptor (uPAR) and plasminogen activator inhib-
itor (PAl-i) can bind vitronectin, an ECM component. The ratio
of the inhibitor (PAl-i) and the proteinase (uPA) appears to
regulate uPAR adhesion to vitronectin [19]. Furthermore, uPAR
(which is glucosyl-phosphatidylinositol-linked to the cell surface)
can form stable complexes with integrins and inhibit their normal
ligand interactions. The integrin-uPAR complexes are suggested
to transduce signals from vitronectin [201. This intimate structural
and functional interaction between uPAR and integrins blurs the
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distinctions between the roles of proteinases and adhesion mole-
cules and provides a novel mechanism for focalized proteolysis of
ECM such as occurs in processes such as angiogenesis or tumor
cell invasion ([3] has a thorough discussion of focalized matrix
remodeling).
Tissues and organ systems operate in very complex environ-
ments that are constructed over time during development and
must be maintained with great care throughout the lifespan of the
organism despite assaults that threaten tissue homeostasis. To
gain insight into this higher order of complexity, it is important to
establish more comprehensive model systems both in culture and
in transgenic/knockout animals in which the cells of interest
recapitulate complex activities over an extended time period. We
are taking this approach to study the roles of adhesion receptors
in the stepwise differentiation programs of osteoblasts and tro-
phoblast cells, the workhorses of two fascinating tissues, bone and
placenta, which exhibit intensive remodeling activity, not only
during their initial differentiation, but throughout their lifespan.
The studies to be described below illustrate two general principles
that are important to keep in mind when considering the initial
differentiation program, normal physiology and pathology of any
tissue. The first, which we illustrate with osteoblasts, is that cells
can respond to the same matrix signal differently at different
stages of differentiation and maturation. The second, which we
illustrate with the placenta, relates to the extraordinary invest-
ment some cell types make in intricately regulating their adhesion
molecule phenotype during their differentiation and while they
are executing their physiologic function. In the case of the
placenta's principal cell type, the cytotrophoblast, this turns out to
be absolutely essential for normal placentation, and is defective in
the important hypertensive pregnancy disorder, preeclampsia.
Fibronectin is a differentiation-promoting factor for
preosteoblasts, and a survival factor for mature osteoblasts
In the flat bones of the skull (calvaria), bone forms directly from
condensed mesenchyme (intramembranous bone formation)
without requiring the prior laying down of a cartilage model that
matrix-secreting osteoblasts and matrix-resorbing osteoclasts then
remodel and replace (endochondral bone formation). We have
used a well-established culture model [2 1—231 to study the roles of
specific ECM constituents and their integrin receptors in different
stages of osteoblast differentiation. In this model (Fig. 1), preos-
teoblasts are isolated from E21 rat calvaria and over a two to three
week period in culture these cells proliferate, multilayer, and, in
the presence of ascorbate and f3-glycerolphosphate, form nodules
that consist of mature plump osteoblasts that secrete and organize
an extensive fibrillar type I collagen-rich matrix, which becomes
mineralized. The mature nodules also contain osteocyte-like cells
embedded within the mineralized matrix core of the nodule.
When such cultures are analyzed for the presence of ECM and
other proteins that are characteristic of bone, it is clear that ECM
production is closely regulated and that at different stages differ-
entiating osteoblasts have a distinctive matrix phenotype [22—24].
It is also clear that although type I collagen is known to comprise
more than 90% of bone ECM, several other matrix molecules are
present, some of which are highly characteristic of bone (such as
bone sialoprotein and osteocalcin). FN is also present [25, 26] and
we were curious about its role in osteogenesis, given previous data
showing that perturbing cell-FN interactions suppresses osteo-
Matrix
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Fig. 1. Fibronectin is required for morphogenesis of immature osteoblasts
and for suivival of mature osteoblasts. Rat fetal calvarial osteoblasts form
mineralized nodules over a 2 to 3 week period in vitro. A. Immature
proliferating osteoblasts form a confluent monolayer by D3. B and C. In
the presence of ascorbate, the culture undergoes multilayering and
nodules form and mature from days 7 to 10. Nodule formation, but not
multilayering, is inhibited if anti-FN or central cell binding fragments of
FN are present continuously starting from day 3 [23]. D. In the presence
of f3-glycerolphosphate, nodules mineralize by day 14. If anti-FN is added
at day 13 or later, about 95% of the cells in the culture undergo
programmed cell death [30].
genic differentiation of MG-63 osteosarcoma cells [27], while
amplification of the integrin a51 FN receptor promotes differ-
entiation of these cells [28].
We therefore treated osteoblast cultures at different stages with
antibody against FN, or with soluble fragments representing
several regions of the FN molecule: both kinds of treatments were
attempts to disrupt normal osteoblast-FN interactions [23]. Addi-
tion of anti-FN to confluent cultures of immature osteoblasts
(culture day 3) inhibited nodule formation by more than 75% and
suppressed expression of mRNA for alkaline phosphatase and
osteocalcin, which are early and late markers for osteoblast
differentiation, respectively. Nonimmune IgG-treated control cul-
tures exhibited normal nodule formation starting at day 7 to 8.
The anti-FN treatment was non-toxic and reversible: when the
antibody was removed, differentiation and nodule formation
resumed. Similar results occurred as long as the anti-FN was
added prior to nodule initiation (day 6). Addition to the cultures
of soluble fragments of FN containing the central cell binding
domain, but lacking other regions of FN, also blocked nodule
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formation [23], as did a function-perturbing antibody against the
cs5 subunit of the specific integrin a5j31 FN receptor [29].
Surprisingly, when anti-FN was added to mature osteoblast
cultures (day 13), in which nodules had formed and become
mineralized, over 90% of the cells in the culture died within 24
hours [301. Although there was some cell shape change following
addition of the anti-FN, the cells remained attached, and no
floating cells were observed during the 24 hour period. Cell nuclei
were condensed and apoptotic bodies were evident throughout
the culture in both nodular and internodular cells. The nuclear
changes were evident prior to extracellular lactate dehydrogenase,
an indicator of plasma membrane integrity, suggesting that the
cells in these mature osteoblast cultures were undergoing pro-
grammed cell death in response to anti-FN. Addition of antibod-
ies against TN or type I collagen to mature osteoblast cultures had
no effect on survival, indicating that the response was related to
perturbing osteoblast—FN interactions.
Although the mechanisms are still unclear, the extensive cell
death in these cultures may be an exaggerated manifestation of a
more targeted normal process of regulating the number of
osteoblasts in bone. It is estimated that of the number of
matrix-secreting osteoblasts present at a growing bone surface,
less than 30% can be accounted for by the number of osteocytes
and mature bone lining cells present at the same location in a
subsequent resting phase. These data suggest that programmed
cell death may be an important natural mechanism for local
control of osteoblast number [31]. Regardless of the mechanisms,
however, the conclusion is inescapable that in this culture model
at least, immature osteoblasts go from being FN-dependent for
differentiation to being FN-dependent for survival. The next step
is to determine whether this is also the case in vivo. If so,
dissecting the mechanisms underlying this biphasic response to
FN on the part of osteoblasts will be extremely interesting. This
study illustrates clearly that changing either the context of the
extracellular environment or that of intracellular signaling net-
works can lead to distinctive responses to ECM signals. Thus, it is
critical when designing therapeutic agents directed at ECM
components, that one is familiar with the role of that component
at a variety of developmental and physiologic stages.
Placentation and preeclampsia
During placentation in humans, cytotrophoblasts undergo an
epithelial-endothelial transformation as they differentiate, a process
that is defective in the systemic hypertensive pregnancy disorder,
preeclampsia. During establishment of the functional placenta in
humans (placentation), a subset of fetal cytotrophoblast (CTB)
stem cells leaves the fetal compartment and invades the uterine
stroma (interstitial invasion) and vasculature (endovascular inva-
sion) thereby anchoring the fetus to the mother and establishing
the flow of oxygenated blood that bathes the fetal portion of the
placenta (Fig. 2). Once CTB have invaded the superficial vascular
network in the decidua, they work their way upstream in the spiral
arteries, but not veins, and replace the maternal endothelium on
the vessel wall as far as the first third of the myometrium. Once on
the vessel wall, they extensively degrade and remodel the muscu-
lar tunica media of these spiral arterial segments, converting them
from narrow-bore, high-resistance to wide-bore low-resistance
vascular channels capable of efficient transport of arterial blood to
the intervillous space, which surrounds the floating chorionic villi
of the fetal placenta [32—34].
At the start of this remarkable journey, the CTB stem cells of
the anchoring chorionic villus form a polarized monolayer on the
trophoblast basement membrane, continuous with the mononu-
clear CTB layer of floating villi (Fig. 2). This monolayer covers the
stromal core of the villi, which contain fetal blood vessels and
connective tissue cells. These CTB express several cell surface
adhesion receptors characteristic of their epithelial origin, includ-
ing the cs64 integrin laminin receptor and E-cadherin, a calcium-
dependent cell-cell adhesion molecule that is ubiquitously ex-
pressed by epithelia [35, 36]. These receptors promote firm
attachment of CTB to their ECM and to one another, respec-
tively. As CTB differentiate along the invasive pathway, they
intricately modulate their adhesion phenotype such that there are
at least five distinguishable stages of differentiation in which the
CTB adhesion phenotypes are distinctive. These stages are clearly
laid out spatially at the fetal-maternal interface (Fig. 2) and are
therefore amenable to analysis by immunocytochemistry of pla-
cental bed biopsies obtained at the time of elective termination of
pregnancies (gestational ages 8 to 18 weeks) or at term following
Cesarean deliveries (34 to 40 weeks).
After an initial survey of integrin subunit distribution, we
determined that those CTB within the uterine interstitium and
spiral arterioles lost staining for a6/34 and instead stained strongly
for alf3l laminin/collagen receptor [37]. Integrin al/31 is widely
expressed on endothelial cells during development, and this gave
us the first hint that CTB may undergo a comprehensive trans-
formation of their adhesion phenotype so as to resemble the
endothelial cells they replace. Subsequent staining of 10 to 18
week placental bed biopsies for cell adhesion receptors from all
the major families (integrins, cadherins, immunoglobulins, selec-
tins) confirmed this hypothesis. Thus, as they leave the tropho-
blast basement membrane, CTB show reduced staining for E-
cadherin and start staining for VE-cadherin (cadherin 5), which to
date has only been found on vascular endothelial cells. Interstitial,
and especially endovascular CTB, stain strongly for this cadherin,
and also express other adhesion receptors characteristic of endo-
thelial cells, including the crV/33 integrin which is known to be
up-regulated on endothelium during angiogenesis [4], vascular
endothelial adhesion molecule (VCAM)-1 and the a4 subunit of
its integrin receptors (a4pl and a47), and platelet endothelial
adhesion molecule (PECAM)-1 [36]. Invasion assays using anti-
integrin subunit-specific antibodies and isolated primary villus
CTB, which recapitulate their differentiation in vitro [38], indicate
that both al/31 and aVf33 promote CTB invasion, while E-
cadherin restrains CTB invasion [36, 39]. Thus, the switching of
the integrin and cadherin family adhesion receptors by differen-
tiating CTB is related to their acquisition of an invasive pheno-
type.
We hypothesize that the Ig family vascular adhesion molecules
that are up-regulated by CTB contribute to the successful take-
over of the spiral arterial walls by CTB once they have entered
these vessels. Thus, if intravascular CTB must contact maternal
endothelium directly as part of the replacement process, they
could use a4 integrins and aV/33 to contact VCAM-1 and
PECAM-1, respectively, on the endothelium. Once CTB reach the
vessel wall, homophilic PECAM-1 and VE-cadherin interactions
could promote the organization of the CTB into a functional
endothelial-like monolayer. Finally, since once they have colo-
nized the vessel wall, CTB continue to invade the muscular tunica
media of the spiral arterioles, they might use their alf3l and aVI33
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Fig. 2. Diagram of a 12 to 16 weeks gestation
anchoring villus (A V), which spans the fetal and
maternal compartments of the human placenta.
Cytotrophoblast (CTB) stem cells (Zone I)
differentiating along the invasive pathway leave
the trophoblast basement membrane, form an
aggregate (cell column: Zones II & III) and
invade the uterine wall (Zone IV) and maternal
vasculature (Zone V). Zones I-V demarcate
regions in which CTB express distinct adhesion
molecule repertoires. As they differentiate, CTB
adopt an adhesion phenotype similar to that of
endothelial cells. In the pregnancy disorder pre-
eclampsia, E-cadherin and a6134 staining
remain strong and endothelial adhesion
receptors are not detected. aparentheses
indicate reduced staining. Data are pooled from
references [35, 36, 41].
integrins along with their high output of proteinases, especially
MMP-9 [35, 38], to migrate through and remodel these vessels.
Testing this hypothesis will require a more sophisticated in vitro
model in which endothelium and CTB are co-cultured in a
geometry and in the presence of physical forces (for example,
flow) that more closely mimic in vivo conditions.
The importance of this extensive adhesion molecule switching
by CTB for normal placentation is brought home forcefully when
considering the hypertensive pregnancy disorder, preeclampsia. In
the form of the disease considered here, pregnant women with no
previous history of hypertension present with hypertension, pro-
teinurea and fetal intrauterine growth retardation in the second or
third trimester, depending on the severity of the disease. Analysis
of placental bed biopsies taken at Cesarean delivery document
that both interstitial and endovascular invasion by CTB are
restricted to the superficial decidua [33, 40, 41]. As a result,
maternal spiral arteriole segments in the deep decidua and
superficial myometrium are not modified, and remain small-bore
and highly muscular. Thorough immunocytochemical analysis of
the adhesion receptor repertoire of preeclamptic CTB in situ
indicates that they start, but fail to complete, the epithelial-to-
endothelial adhesion phenotype switch executed by CTB in
normal placental tissues. Preeclamptic CTB that are present in
the superficial decidua interstitium and vasculature, the limit of
their penetration, retain strong staining for epithelial markers
(iritegrin a6J34 and E-cadherin), and stain very weakly or not at all
for integrins a11 and aV3, both of which have been shown in
functional studies to be required for invasion by normal CTB in
vitro [36, 39]. They also do not stain for VE-cadherin, PECAM-1
and VCAM-1 [33, 421. These findings lead us to hypothesize that
CTB in preeclampsia fail to adopt an adhesion phenotype re-
quired for optimal interstitial and endovascular invasion to the
appropriate depth in the uterine wall. The resulting failure to
modify the maternal vasculature adequately likely contributes
significantly to the relatively poor perfusion of the fetal placenta
by maternal blood and to the relatively hypoxic environment of
the fetal-maternal interface in preeclampsia (discussed in [43]).
Preeclampsia is a complex set of diseases with a multifactorial
etiology. Although it is a systemic hypertensive disease by the time
the patients experience symptoms, it is likely that the disease
originates early in pregnancy in the developing placenta. In the
subset of patients defined above, defective adhesion molecule
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switching by CTB is but one factor (although we think an
important one) contributing to the disease process. Preeclamptic
CTB show other abnormalities as well, including low expression
levels of protcinases (such as MMP-9) likely to be critical for
invasion [38], and reduced expression of the trophoblast-specific
HLA class-i molecule HLA-G, that is hypothesized to play an
important role in the ability of the fetus to avoid rejection by the
maternal immune system [44]. Since none of the genes for these
molecules is abnormal (the babies are normal if their prematurity
does not compromise their ability to thrive), preeclampsia is a
disorder in which abnormal regulation of hormones, peptide
signaling factors and/or transcription factors is likely to be asso-
ciated with the primary cause. Although the primary cause(s) are
still unclear, we believe that altered expression of adhesion
receptors, proteinases and HLA-G in preeclamptic CTB, espe-
cially as they affect the maternal vasculature of the uterine wall,
are proximal sequellae of the primary cause, and contribute not
only to the local abnormalities in placentation, but also to the
processes that result in systemic disease.
In summary, the systems discussed in this review as well as other
informative models [45] underscore the critical and varied roles
played by adhesion receptors in normal morphogenesis and
differentiation and in ECM homeostasis. Important as they are,
however, they function in a solid state environment with which
peptide signaling factors and proteinases and their inhibitors are
also associated. The functions of these classes of molecules are
interdependent, and together orchestrate morphogenesis and
tissue and ECM homeostasis.
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Appendix
Abbreviations are: CTB, cytotrophoblast; ECM, extracellular matrix;
FC, focal contacts; FN, fibronectin; MMP, matrix metalloproteinase;
PEAM-1, platelet endothelial adhesion molecule-i; SPARC, secreted
protein, acidic and rich in cysteine; TN, tenasein; VCAM-1, vascular
endothelial adhesion molecule-i; VN, vitroneetin.
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